JP2005538051A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005538051A5 JP2005538051A5 JP2004503463A JP2004503463A JP2005538051A5 JP 2005538051 A5 JP2005538051 A5 JP 2005538051A5 JP 2004503463 A JP2004503463 A JP 2004503463A JP 2004503463 A JP2004503463 A JP 2004503463A JP 2005538051 A5 JP2005538051 A5 JP 2005538051A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrate
- acid
- pharmaceutically acceptable
- compound
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 5
- -1 NH 2 Inorganic materials 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 230000003013 cytotoxicity Effects 0.000 claims description 3
- 231100000135 cytotoxicity Toxicity 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 239000000706 filtrate Substances 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- 239000012296 anti-solvent Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- HTMGQIXFZMZZKD-UHFFFAOYSA-N 5,6,7,8-tetrahydroisoquinoline Chemical compound N1=CC=C2CCCCC2=C1 HTMGQIXFZMZZKD-UHFFFAOYSA-N 0.000 claims 1
- YQDGQEKUTLYWJU-UHFFFAOYSA-N 5,6,7,8-tetrahydroquinoline Chemical compound C1=CC=C2CCCCC2=N1 YQDGQEKUTLYWJU-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- LGGHDPFKSSRQNS-UHFFFAOYSA-N Tariquidar Chemical compound C1=CC=CC2=CC(C(=O)NC3=CC(OC)=C(OC)C=C3C(=O)NC3=CC=C(C=C3)CCN3CCC=4C=C(C(=CC=4C3)OC)OC)=CN=C21 LGGHDPFKSSRQNS-UHFFFAOYSA-N 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000004687 hexahydrates Chemical class 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 238000010792 warming Methods 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000012124 AIDS-related disease Diseases 0.000 description 1
- 206010001986 Amoebic dysentery Diseases 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37975902P | 2002-05-14 | 2002-05-14 | |
| PCT/GB2003/002060 WO2003095447A1 (en) | 2002-05-14 | 2003-05-13 | Process for the preparation of a hydrate of an anthranilic acid derivative |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005538051A JP2005538051A (ja) | 2005-12-15 |
| JP2005538051A5 true JP2005538051A5 (https=) | 2006-06-15 |
| JP4464814B2 JP4464814B2 (ja) | 2010-05-19 |
Family
ID=29420557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004503463A Expired - Fee Related JP4464814B2 (ja) | 2002-05-14 | 2003-05-13 | アントラニル酸誘導体の水和物の製造方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7524861B2 (https=) |
| EP (1) | EP1506188B1 (https=) |
| JP (1) | JP4464814B2 (https=) |
| KR (1) | KR101060971B1 (https=) |
| CN (1) | CN100349888C (https=) |
| AT (1) | ATE423778T1 (https=) |
| AU (1) | AU2003233899B2 (https=) |
| BR (1) | BR0309990A (https=) |
| CA (1) | CA2485430C (https=) |
| DE (1) | DE60326341D1 (https=) |
| WO (1) | WO2003095447A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100557093B1 (ko) | 2003-10-07 | 2006-03-03 | 한미약품 주식회사 | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 |
| US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| LT2502911T (lt) | 2004-06-24 | 2017-09-11 | Vertex Pharmaceuticals Incorporated | Atp surišančios kasetės transporterių moduliatoriai |
| FR2873585B1 (fr) * | 2004-07-27 | 2006-11-17 | Aventis Pharma Sa | Nouvelles formulations galeniques de principes actifs |
| CA2634113A1 (en) * | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of abc transporters |
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| GB0706072D0 (en) * | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| SI2408750T1 (sl) | 2009-03-20 | 2015-11-30 | Vertex Pharmaceuticals Incorporated | Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| EP2819670A1 (en) | 2012-02-27 | 2015-01-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
| PE20160605A1 (es) | 2013-07-30 | 2016-07-20 | Gilead Connecticut Inc | Formulaciones de inhibidores de la syk |
| KR101810798B1 (ko) | 2013-07-30 | 2017-12-19 | 질레드 코네티컷 인코포레이티드 | Ｓｙｋ 억제제의 다형체 |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| CN103804352B (zh) * | 2014-01-23 | 2017-06-13 | 中国药科大学 | 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用 |
| KR20170063954A (ko) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정 |
| CN104327046B (zh) * | 2014-10-14 | 2017-11-17 | 中国药科大学 | 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用 |
| CN104434947B (zh) * | 2014-11-07 | 2016-11-09 | 滨州医学院附属医院 | 一种抗胆管癌的药物组合物及其应用 |
| EP3378858A1 (en) * | 2017-03-21 | 2018-09-26 | Bioprojet | Tetrahydrate of h3 ligand, its process of preparation and pharmaceutical compositions comprising the same |
| EP3672974A1 (en) | 2017-08-25 | 2020-07-01 | Gilead Sciences, Inc. | Polymorphs of syk inhibitors |
| US11339168B2 (en) | 2019-02-22 | 2022-05-24 | Kronos Bio, Inc. | Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors |
| AU2021358977A1 (en) * | 2020-10-07 | 2023-04-27 | Health Hope Pharma Hk Limited | Acetamido-phenylbenzamide derivatives and methods of using the same |
| CN112724124A (zh) * | 2021-01-18 | 2021-04-30 | 林剑雄 | 4-羟基喹啉类衍生物及其制备方法和在抗肿瘤药物中的应用 |
| CN117304105A (zh) * | 2023-08-18 | 2023-12-29 | 中国科学院基础医学与肿瘤研究所(筹) | 一种靶向抑制ABCB1(P-gp)的化合物及制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100220538B1 (ko) * | 1991-01-11 | 1999-09-15 | 뮈쉘 쥐르밀 | 아크리딘 유도체 |
| CN100354265C (zh) * | 1996-10-18 | 2007-12-12 | 埃克森诺瓦有限公司 | 邻氨基苯甲酸衍生物及其制备方法和作为多种抗性调节剂的用途 |
| GB9717576D0 (en) * | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
-
2003
- 2003-05-13 KR KR1020047018344A patent/KR101060971B1/ko not_active Expired - Fee Related
- 2003-05-13 CN CNB038159295A patent/CN100349888C/zh not_active Expired - Fee Related
- 2003-05-13 CA CA2485430A patent/CA2485430C/en not_active Expired - Fee Related
- 2003-05-13 WO PCT/GB2003/002060 patent/WO2003095447A1/en not_active Ceased
- 2003-05-13 US US10/513,986 patent/US7524861B2/en not_active Expired - Fee Related
- 2003-05-13 AT AT03727661T patent/ATE423778T1/de not_active IP Right Cessation
- 2003-05-13 AU AU2003233899A patent/AU2003233899B2/en not_active Ceased
- 2003-05-13 EP EP03727661A patent/EP1506188B1/en not_active Expired - Lifetime
- 2003-05-13 BR BR0309990-3A patent/BR0309990A/pt not_active IP Right Cessation
- 2003-05-13 DE DE60326341T patent/DE60326341D1/de not_active Expired - Lifetime
- 2003-05-13 JP JP2004503463A patent/JP4464814B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005538051A5 (https=) | ||
| JP4464814B2 (ja) | アントラニル酸誘導体の水和物の製造方法 | |
| ES2687985T3 (es) | Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer colorrectal | |
| ES2717898T3 (es) | Efecto potenciador para agentes antitumorales | |
| DE794794T1 (de) | Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika | |
| RU99115746A (ru) | Новые соединения с анальгезирующим действием | |
| TW202317532A (zh) | Aak1抑制劑及其用途 | |
| JP6355645B2 (ja) | 活性成分としてテトラゾール誘導体を含む、溶解性が改善された固体分散体 | |
| CN102159541A (zh) | 抗癌口服制剂 | |
| JPS5995269A (ja) | 抗てんかん性医薬品 | |
| WO2021055705A1 (en) | Biaminoquinolines and nanoformulations for cancer treatment | |
| JP7839214B2 (ja) | Ｃ－ｍｅｔキナーゼ阻害剤としての化合物の結晶及びその調製方法及びその使用 | |
| JP2011512370A (ja) | ベンゾフェナントリジン構造を有する抗腫瘍薬およびそれらを含有する製剤 | |
| JP2024009114A (ja) | ミネラルコルチコイド受容体拮抗剤としての化合物の結晶形及びその調製方法 | |
| CA3006502A1 (en) | Crystalline forms of quinolone analogs and their salts | |
| WO2008124823A1 (en) | Method of treating melanoma | |
| CN112805288B (zh) | 含有n-杂环卡宾配体的铱(iii)配合物、其合成及其在癌症治疗中的用途 | |
| DK2649048T3 (en) | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USE THEREOF | |
| US7754733B2 (en) | Crystalline topotecan hydrochloride product and process for making the same | |
| JP7719787B2 (ja) | アルテミシニン化合物、５－アミノレブリン酸またはメチル－５－アミノレブリン酸、および化学療法剤の医薬配合物 | |
| JP6523782B2 (ja) | 新規な結晶性化合物 | |
| CA2568993C (fr) | Sel de sodium monohydrate du s-tenatoprazole et application en tant qu'inhibiteur de la pompe a protons | |
| WO2021088762A1 (zh) | 肝靶向药、其药物组合物及其用途 | |
| WO2025160291A1 (en) | Prodrugs based on tumor targeting near infrared dye-drug conjugates (ddc) | |
| RU2021129866A (ru) | Ингибирование циклического amp-чувствительного элемент-связывающего белка (creb) |